Poteat T, Bothma R, Maposa I, Hendrickson C, Meyer-Rath G, Hill N
JMIR Res Protoc. 2024; 13:e64373.
PMID: 39269745
PMC: 11437231.
DOI: 10.2196/64373.
Mtisi T, Kouamou V, Morse G, Dzinamarira T, Ndhlovu C
J Infect Public Health. 2024; 17(9):102500.
PMID: 39173560
PMC: 11393767.
DOI: 10.1016/j.jiph.2024.102500.
Coyle R, Morrow M, Mann S, Mainella V, Ellis S, Schwab S
Clin Infect Dis. 2024; 79(5):1233-1241.
PMID: 38636950
PMC: 11581703.
DOI: 10.1093/cid/ciae212.
Landovitz R, Tao L, Yang J, de Boer M, Carter C, Das M
Clin Infect Dis. 2024; 79(5):1197-1207.
PMID: 38484128
PMC: 7616831.
DOI: 10.1093/cid/ciae143.
Marrazzo J, Tao L, Becker M, Leech A, Taylor A, Ussery F
JAMA. 2024; 331(11):930-937.
PMID: 38427359
PMC: 10951736.
DOI: 10.1001/jama.2024.0464.
Quantification of Antiviral Drug Tenofovir (TFV) by Surface-Enhanced Raman Spectroscopy (SERS) Using Cumulative Distribution Functions (CDFs).
Butler M, Hrncirova J, Clark M, Dutta S, Cooper J
ACS Omega. 2024; 9(1):1310-1319.
PMID: 38222633
PMC: 10785616.
DOI: 10.1021/acsomega.3c07641.
Biomarker-confirmed suboptimal adherence to isoniazid preventive therapy among children with HIV in western Kenya.
Onyango D, van der Sande M, Yuen C, Were J, Mecha J, Njagi L
AIDS. 2023; 38(1):39-47.
PMID: 37773037
PMC: 10840836.
DOI: 10.1097/QAD.0000000000003719.
Steady-state pharmacokinetics of plasma tenofovir alafenamide (TAF), tenofovir (TFV) and emtricitabine (FTC), and intracellular TFV-diphosphate and FTC-triphosphate in HIV-1 infected old Japanese patients treated with bictegravir/FTC/TAF.
Tran H, Tsuchiya K, Kawashima A, Watanabe K, Hayashi Y, Ryu S
Glob Health Med. 2023; 5(4):216-222.
PMID: 37655187
PMC: 10461328.
DOI: 10.35772/ghm.2023.01060.
Development and Preliminary Validation of the PrEP Empowerment Scale.
Crockett K, Batey D, Turan B
AIDS Behav. 2023; 27(11):3645-3650.
PMID: 37166688
PMC: 10592504.
DOI: 10.1007/s10461-023-04078-0.
A Novel Algorithm to Improve PrEP Adherence Monitoring Using Dried Blood Spots.
Devanathan A, Dumond J, Anderson D, Moody K, Poliseno A, Schauer A
Clin Pharmacol Ther. 2023; 113(4):896-903.
PMID: 36622798
PMC: 10023501.
DOI: 10.1002/cpt.2845.
Contingency Management and Pre-Exposure Prophylaxis Adherence Support Services (CoMPASS): A hybrid type 1 effectiveness-implementation study to promote HIV risk reduction among people who inject drugs.
Sung M, Viera A, Esserman D, Tong G, Davidson D, Aiudi S
Contemp Clin Trials. 2022; 125:107037.
PMID: 36460267
PMC: 9918697.
DOI: 10.1016/j.cct.2022.107037.
Long-Acting Treatments for Hepatitis B.
Thomas D, Kiser J, Baum M
Clin Infect Dis. 2022; 75(Suppl 4):S517-S524.
PMID: 36410388
PMC: 9678382.
DOI: 10.1093/cid/ciac718.
Tenofovir-Diphosphate in Dried Blood Spots vs Tenofovir in Urine/Plasma for Oral Preexposure Prophylaxis Adherence Monitoring.
Niu X, Kubiak R, Siriprakaisil O, Klinbuyaem V, Sukrakanchana P, Cressey R
Open Forum Infect Dis. 2022; 9(8):ofac405.
PMID: 36004315
PMC: 9394764.
DOI: 10.1093/ofid/ofac405.
Adherence Predictors in Pregnant Women Living with HIV on Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate.
Eke A
J Pharm Drug Res. 2022; 5(1):585-593.
PMID: 35845086
PMC: 9281900.
Oral pre-exposure prophylaxis preference, uptake, adherence and continuation among adolescent girls and young women in Kampala, Uganda: a prospective cohort study.
Mayanja Y, Kamacooko O, Lunkuse J, Muturi-Kioi V, Buzibye A, Omali D
J Int AIDS Soc. 2022; 25(5):e25909.
PMID: 35543110
PMC: 9092160.
DOI: 10.1002/jia2.25909.
Study protocol of a randomized controlled trial comparing two linkage models for HIV prevention and treatment in justice-involved persons.
Springer S, Nijhawan A, Knight K, Kuo I, Di Paola A, Schlossberg E
BMC Infect Dis. 2022; 22(1):380.
PMID: 35428213
PMC: 9013109.
DOI: 10.1186/s12879-022-07354-x.
Adaptation and validation of simple tools to screen and monitor for oral PrEP adherence.
Zissette S, Tolley E, Martinez A, Hanif H, Gill K, Mugo N
PLoS One. 2021; 16(5):e0251823.
PMID: 34043657
PMC: 8158999.
DOI: 10.1371/journal.pone.0251823.
A comparison of covariate selection techniques applied to pre-exposure prophylaxis (PrEP) drug concentration data in men and transgender women at risk for HIV.
Peterson S, Ibrahim M, Anderson P, Moore C, MaWhinney S
J Pharmacokinet Pharmacodyn. 2021; 48(5):655-669.
PMID: 34013454
DOI: 10.1007/s10928-021-09763-y.
Point-of-Care Test for Assessing Tenofovir Adherence: Feasibility and Recommendations from Women in an Oral PrEP Program in Kenya and Their Healthcare Providers.
Thuo N, Polay M, Leddy A, Ngure K, Chatterhee P, Gandhi M
AIDS Behav. 2021; 25(11):3617-3629.
PMID: 33893877
PMC: 9271229.
DOI: 10.1007/s10461-021-03255-3.
Short Communication: A Descriptive Analysis of Dried Blood Spot Adherence Testing Among Ugandans with HIV Presenting with Cryptococcal Meningitis.
Lofgren S, Nicol M, Kandole T, Castillo-Mancilla J, Anderson P, Mpoza E
AIDS Res Hum Retroviruses. 2021; 37(7):529-533.
PMID: 33677986
PMC: 8260886.
DOI: 10.1089/AID.2020.0202.
